FDA (CBER)
GUIDANCE DRAFT
Potency Assessment of Active Immunotherapy Products
Published: 8/19/2026Detected: 9/4/2026
Summary preview
Clarifies FDA expectations for potency assessment strategies for active immunotherapy products, which may influence how sponsors design potency assays and justify assay suitability across product lifecycle changes.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
infectious_disease
oncology
rare_diseases
manufacturing
quality
clinical
safety
labeling
#active immunotherapy
#potency assay
Official Source Document Source Verified
Access the original document directly from FDA CBER.
More from FDA (CBER)
- Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus: Guidance for Industry11/3/2026
- Guidance for Industry: Potency Assurance for Cellular and Gene Therapy Products11/2/2026
- Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management10/27/2026
- Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Guidance for Industry10/14/2026
- Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Guidance for Industry10/14/2026